{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:24:18Z","timestamp":1792027458041,"version":"4.4.0"},"reference-count":25,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Macular edema (ME) secondary to retinal vein occlusion (RVO) is a significant cause of vision impairment. Many patients show suboptimal responses to anti-vascular endothelial growth factor (anti-VEGF) monotherapy, prompting the exploration of alternative treatments. Faricimab is a bispecific antibody that targets VEGF-A and angiopoietin-2. We report 9-month real-world outcomes of switching to faricimab in therapy-resistant RVO-associated ME. Methods: In this retrospective study at a single tertiary center, patients with persistent or recurrent ME despite prior treatments (ranibizumab, aflibercept, or dexamethasone implant) were switched to faricimab. All eyes received a loading phase of four monthly faricimab injections, followed by a treat-and-extend regimen individualized per response. Key outcomes included best-corrected visual acuity (BCVA, logMAR), the central subfield thickness (CST, \u03bcm), and the intraretinal fluid (IRF) status on optical coherence tomography, assessed from the baseline (month 0, mo0) through the loading phase (mo1\u2013mo3) and at month 9 (mo9). Results: Nineteen eyes (19 patients, mean age 64.8 years) were analyzed. The median BCVA improved from 0.20 to 0.00 logMAR by month 3 (p &lt; 0.01) and was maintained at month 9. The median CST decreased from 325 \u03bcm at the baseline to 285 \u03bcm at month 3 (p &lt; 0.01) and remained at 285 \u03bcm at month 9. IRF was present in 100% of eyes at the baseline, 26% at month 3, and 26% at month 9 (p &lt; 0.01 for the baseline vs. month 9). Among eyes previously on anti-VEGF therapy (n = 14), the median treatment interval increased from 45.50 days at the baseline to 56.50 days at month 9 (p = 0.01; \u03b4 = 0.86). No intraocular inflammation or other adverse events were observed in this cohort over nine months. Conclusions: In this retrospective series, switching to faricimab was associated with improvements in vision and retinal anatomy that were maintained over 9 months; injection intervals were extended in a subset of eyes. These exploratory findings warrant confirmation in larger, controlled studies to define long-term effectiveness, safety, and dosing strategies.<\/jats:p>","DOI":"10.3390\/jcm14207197","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T10:12:29Z","timestamp":1760523149000},"page":"7197","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Extended Real-World Efficacy of Faricimab in Therapy-Resistant Macular Edema Due to Retinal Vein Occlusion: 9-Month Follow-Up Results"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-9025-259X","authenticated-orcid":false,"given":"Michael","family":"Hafner","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, LMU University Hospital, LMU Munich, 81377 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina R.","family":"Herold","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, LMU University Hospital, LMU Munich, 81377 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kufner","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, LMU University Hospital, LMU Munich, 81377 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5883-2529","authenticated-orcid":false,"given":"Franziska","family":"Eckardt","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, LMU University Hospital, LMU Munich, 81377 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Asani","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, LMU University Hospital, LMU Munich, 81377 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5580-612X","authenticated-orcid":false,"given":"Siegfried G.","family":"Priglinger","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, LMU University Hospital, LMU Munich, 81377 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5357-7469","authenticated-orcid":false,"given":"Johannes","family":"Schiefelbein","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, LMU University Hospital, LMU Munich, 81377 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMcp1003934","article-title":"Clinical practice. Retinal-vein occlusion","volume":"363","author":"Wong","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/eye.2011.92","article-title":"The burden of disease of retinal vein occlusion: Review of the literature","volume":"25","author":"Laouri","year":"2011","journal-title":"Eye"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/mt.2008.10","article-title":"Ranibizumab for macular edema due to retinal vein occlusions: Implication of VEGF as a critical stimulator","volume":"16","author":"Campochiaro","year":"2008","journal-title":"Mol. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000502041","article-title":"Guidelines for the Management of Retinal Vein Occlusion by the European Society of Retina Specialists (EURETINA)","volume":"242","author":"Gerendas","year":"2019","journal-title":"Ophthalmologica"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"621","DOI":"10.2147\/OPTH.S163859","article-title":"Anti-VEGF treatment of macular edema associated with retinal vein occlusion: Patterns of use and effectiveness in clinical practice (ECHO study report 2)","volume":"12","author":"Jumper","year":"2018","journal-title":"Clin. Ophthalmol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/IAE.0000000000002475","article-title":"INTRAVITREAL DEXAMETHASONE IMPLANT MIGRATION INTO THE ANTERIOR CHAMBER: A Multicenter Study From the Pan-American Collaborative Retina Study Group","volume":"40","author":"Goncalves","year":"2020","journal-title":"Retina"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1016\/j.ophtha.2011.05.014","article-title":"Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results","volume":"118","author":"Haller","year":"2011","journal-title":"Ophthalmology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/nrd.2016.278","article-title":"Therapeutic targeting of the angiopoietin-TIE pathway","volume":"16","author":"Saharinen","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.15252\/emmm.201505889","article-title":"Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases","volume":"8","author":"Regula","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/s41433-020-01377-x","article-title":"Angiopoietin\/Tie2 signalling and its role in retinal and choroidal vascular diseases: A review of preclinical data","volume":"35","author":"Joussen","year":"2021","journal-title":"Eye"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"100302","DOI":"10.1016\/j.xops.2023.100302","article-title":"BALATON and COMINO: Phase III Randomized Clinical Trials of Faricimab for Retinal Vein Occlusion: Study Design and Rationale","volume":"3","author":"Hattenbach","year":"2023","journal-title":"Ophthalmol. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.ophtha.2024.01.029","article-title":"Efficacy and Safety of Faricimab for Macular Edema due to Retinal Vein Occlusion: 24-Week Results from the BALATON and COMINO Trials","volume":"131","author":"Tadayoni","year":"2024","journal-title":"Ophthalmology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","article-title":"Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): Two randomised, double-masked, phase 3 trials","volume":"399","author":"Wykoff","year":"2022","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): Two randomised, double-masked, phase 3, non-inferiority trials","volume":"399","author":"Heier","year":"2022","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.oret.2025.03.005","article-title":"Faricimab Treat-and-Extend Dosing for Macular Edema Due to Retinal Vein Occlusion: 72-Week Results from the BALATON and COMINO Trials","volume":"9","author":"Danzig","year":"2025","journal-title":"Ophthalmol. Retin."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"756","DOI":"10.5301\/ejo.5000943","article-title":"Real-world outcomes of anti-VEGF treatment for retinal vein occlusion in Portugal","volume":"27","author":"Marques","year":"2017","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s40942-025-00703-3","article-title":"Short-term real-world effectiveness of faricimab on macular edema due to retinal vein occlusion","volume":"11","author":"Hirakata","year":"2025","journal-title":"Int. J. Retin. Vitr."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Hikichi, T., Kurabe, H., Notoya, A., Oguro, Y., Hirano, M., and Doi, Y. (Jpn. J. Ophthalmol., 2025). Short-term outcomes of switching to faricimab for macular edema secondary to retinal vein occlusion, Jpn. J. Ophthalmol.","DOI":"10.1007\/s10384-025-01237-9"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Hafner, M., Herold, T.R., Kufner, A., Asani, B., Anschutz, A., Eckardt, F., Priglinger, S.G., and Schiefelbein, J. (2025). Switching to Faricimab in Therapy-Resistant Macular Edema Due to Retinal Vein Occlusion: Initial Real-World Efficacy Outcomes. J. Clin. Med., 14.","DOI":"10.3390\/jcm14072454"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/S0161-6420(89)32814-4","article-title":"Detection of diabetic macular edema. Ophthalmoscopy versus photography\u2014Early Treatment Diabetic Retinopathy Study Report Number 5. The ETDRS Research Group","volume":"96","author":"Kinyoun","year":"1989","journal-title":"Ophthalmology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s00417-013-2528-8","article-title":"Early peripheral laser photocoagulation of nonperfused retina improves vision in patients with central retinal vein occlusion (Results of a proof of concept study)","volume":"252","author":"Rehak","year":"2014","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1001\/jamaophthalmol.2024.3828","article-title":"Sterile Intraocular Inflammation Associated With Faricimab","volume":"142","author":"Cozzi","year":"2024","journal-title":"JAMA Ophthalmol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1097\/IAE.0000000000004394","article-title":"INTRAOCULAR INFLAMMATION ASSOCIATED WITH FARICIMAB THERAPY: One-Year Real-World Outcomes","volume":"45","author":"Montesel","year":"2025","journal-title":"Retina"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/s41433-025-03616-5","article-title":"1-Year real-world outcomes of faricimab in previously treated neovascular age-related macular degeneration","volume":"39","author":"Janmohamed","year":"2025","journal-title":"Eye"},{"key":"ref_25","unstructured":"Roche (2025, September 05). European Commission Approves Roche\u2019s Vabysmo for Treatment of Retinal Vein Occlusion (RVO) [Internet]. Available online: https:\/\/www.roche.com\/media\/releases\/med-cor-2024-07-30?utm."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/20\/7197\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T10:40:10Z","timestamp":1760524810000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/20\/7197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":25,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["jcm14207197"],"URL":"https:\/\/doi.org\/10.3390\/jcm14207197","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,13]]}}}